Nkar­ta drops a can­cer pro­gram, putting au­toim­mune front and cen­ter. Will it pay off?

Nkar­ta hit the brakes on one of its lead pro­grams Thurs­day af­ter­noon, de­pri­or­i­tiz­ing a CAR-NK ther­a­py de­signed to treat an ag­gres­sive form of leukemia af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER